Jump to main content
Jump to site search


A Micellar Cisplatin Prodrug Simultaneously Eliminates both Cancer Cells and Cancer Stem Cells in Lung Cancer

Abstract

Platinum-based chemotherapy as first-line treatments for lung cancers encounter insufficient selectivity, severe side effects and drug resistance in clinics. In this study, we developed an amphiphilic prodrug of cisplatin-poly(ethylene glycol)-block-polycaprolactone and demonstrated that the prodrug formed micellar nanoparticles NPPt(IV) with average diameter of ~100 nm. NPPt(IV) released platinum in response to intracellular acidic and reductive environment, and in turn induced significant anti-proliferative activity in lung cancer cells. More importantly, NPPt(IV) exhibited prominent inhibitory effect on CD133+ lung cancer stem cells (CSCs) and suppressed tumor growth in vivo. Unlike cisplatin treatment which eventually enrich CSCs, NPPt(IV) treatment prevents accumulation of CD133+ lung CSCs in tumors. Therefore, NPPt(IV) simutaneously targeting CSCs and non-CSCs might represent a superior strategy to improve conventional anticancer therapy directed predominnantly to tumor bulk populations.

Back to tab navigation
Please wait while Download options loads

Publication details

The article was received on 30 Mar 2017, accepted on 15 May 2017 and first published on 18 May 2017


Article type: Paper
DOI: 10.1039/C7BM00278E
Citation: Biomater. Sci., 2017, Accepted Manuscript
  •   Request permissions

    A Micellar Cisplatin Prodrug Simultaneously Eliminates both Cancer Cells and Cancer Stem Cells in Lung Cancer

    Y. Zhu, C. Sun, S. Shen, M. Khan, Y. Zhao, Y. Liu, Y. Wang and J. Wang, Biomater. Sci., 2017, Accepted Manuscript , DOI: 10.1039/C7BM00278E

Search articles by author